Last reviewed · How we verify
NCT07033455
A Trial of HRS-1893 in Healthy Volunteers
EARLY_PHASE1 trial testing HRS-1893 in Hypertrophic Cardiomyopathy in 20 participants. Completed in 30 October 2025.
5 September 2025
Quick facts
| Lead sponsor | Atridia Pty Ltd. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 25 June 2025 |
| Primary completion | 5 September 2025 |
| Estimated completion | 30 October 2025 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- HRS-1893 — full drug profile →
Conditions studied
- Hypertrophic Cardiomyopathy — all drugs for Hypertrophic Cardiomyopathy →
Sponsor
Atridia Pty Ltd. — full company profile →
Who can join
Adults 18 to 55, any sex, with Hypertrophic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the safety and PK characteristics of a single oral dose of HRS-1893 in healthy voluunters.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07033455
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HRS-1893
Trials testing the same drug.
- NCT06775834 — Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function · Phase 1 · completed
- NCT05879523 — A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy · Phase 1 · completed
Other recruiting trials for Hypertrophic Cardiomyopathy
Currently open trials in the same condition.
- NCT07361289 — A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopa · recruiting
- NCT06490250 — Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients · NA · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT06549608 — A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada · active not recruiting
- NCT05939700 — Mavacamten Pregnancy Surveillance Program · recruiting
Other Atridia Pty Ltd. trials
Trials by the same sponsor.
- NCT07358377 — To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negati · Phase 1 · not yet recruiting
- NCT07390747 — A Trial of SHR-2173 in Healthy Volunteers · Phase 1 · recruiting
- NCT07238647 — A Trial of HRS-5817 in Obese Participants · EARLY_PHASE1 · recruiting
- NCT07078695 — A Trial of SHR-1139 in Healthy Volunteers · Phase 1 · active not recruiting
- NCT06830850 — A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07033455 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Atridia Pty Ltd.
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07033455.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing